Although they are attractive targets in breast cancer, therapies targeting receptor tyrosine kinases (RTKs) face challenges such as structural mutations of the receptors, amplification of their genes and activation of alternative signaling pathways that affect their efficacy [20]. This evidence concerns the gene NTRK1 and breast cancer.